BMP-2 and -4 produced by vascular smooth muscle cells from atherosclerotic lesions induce monocyte chemotaxis through direct BMPRII activation

Atherosclerosis

Volumn 235, Issue 1, 2014, Pages 45-55

  Simões Sato, Alex Yuri ^a,b   Bub, Guilherme Linhares ^a,b   Campos, Alexandre Holthausen ^a,b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b Centro de Pesquisa Experimental   (Brazil)

Author keywords

Atherosclerosis; BMP; Chemotaxis; Gremlin; Inflammation; Monocyte; Smooth muscle cell

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHEMOATTRACTANT; GREMLIN PROTEIN; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; BMPR2 PROTEIN, HUMAN; BMPR2 PROTEIN, MOUSE; GREM1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELLULAR SECRETION; CHEMOTAXIS; ENZYME ACTIVATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MONOCYTE CHEMOTAXIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; ANIMAL; C57BL MOUSE; CELL MOTION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MONOCYTE; MUTATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL MOVEMENT; CHEMOTAXIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; MUTATION; MYOCYTES, SMOOTH MUSCLE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84901821282     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.030     Document Type: Article

References (46)

1. Butoi E.D., Gan A.M., Manduteanu I., Stan D., Calin M., Pirvulescu M., et al. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta 2011, 1813:2026-2035.
2. Matsumoto T., Kobayashi T., Kamata K. Diabetic conditions act as matchmaker for monocytes and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2010, 298:H731-733.
3. Gerszten R.E., Tager A.M. The monocyte in atherosclerosis - should I stay or should I go now?. NEngl J Med 2012, 366:1734-1736.
4. Dutta P., Courties G., Wei Y., Leuschner F., Gorbatov R., Robbins C.S., et al. Myocardial infarction accelerates atherosclerosis. Nature 2012, 487:325-329.
5. Feig J.E., Pineda-Torra I., Sanson M., Bradley M.N., Vengrenyuk Y., Bogunovic D., et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. JClin Invest 2010, 120:4415-4424.
6. Feig J.E., Rong J.X., Shamir R., Sanson M., Vengrenyuk Y., Liu J., et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A 2011, 108:7166-7171.
7. Potteaux S., Gautier E.L., Hutchison S.B., van Rooijen N., Rader D.J., Thomas M.J., et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of apoe-/- mice during disease regression. JClin Invest 2011, 121:2025-2036.
8. Bhardwaj S., Roy H., Babu M., Shibuya M., Yla-Herttuala S. Adventitial gene transfer of VEGFR-2 specific VEGF-e chimera induces MCP-1 expression in vascular smooth muscle cells and enhances neointimal formation. Atherosclerosis 2011, 219:84-91.
9. Hayakawa E., Yoshimoto T., Sekizawa N., Sugiyama T., Hirata Y. Overexpression of receptor for advanced glycation end products induces monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cell line. JAtheroscler Thromb 2012, 19:13-22.
10. Ollivier V., Faure S., Tarantino N., Chollet-Martin S., Deterre P., Combadiere C., et al. Fractalkine/CX3CL1 production by human aortic smooth muscle cells impairs monocyte procoagulant and inflammatory responses. Cytokines 2003, 21:303-311.
11. Sovershaev M.A., Egorina E.M., Bogdanov V.Y., Seredkina N., Fallon J.T., Valkov A.Y., et al. Bone morphogenetic protein-7 increases thrombogenicity of lipid-rich atherosclerotic plaques via activation of tissue factor. Thromb Res 2010, 126:306-310.
12. Hayashi K., Nakamura S., Nishida W., Sobue K. Bone morphogenetic protein-induced Msx1 and Msx2 inhibit myocardin-dependent smooth muscle gene transcription. Mol Cell Biol 2006, 26:9456-9470.
13. Lagna G., Ku M.M., Nguyen P.H., Neuman N.A., Davis B.N., Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. JBiol Chem 2007, 282:37244-37255.
14. Spiekerkoetter E., Guignabert C., de Jesus Perez V., Alastalo T.P., Powers J.M., Wang L., et al. S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4. Circ Res 2009, 105:639-647. 613 p following 647.
15. Ikeda K., Souma Y., Akakabe Y., Kitamura Y., Matsuo K., Shimoda Y., et al. Macrophages play a unique role in the plaque calcification by enhancing the osteogenic signals exerted by vascular smooth muscle cells. Biochem Biophys Res Commun 2012, 425:39-44.
16. Miller J.D., Weiss R.M., Heistad D.D. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011, 108:1392-1412.
17. Yao Y., Bennett B.J., Wang X., Rosenfeld M.E., Giachelli C., Lusis A.J., et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res 2010, 107:485-494.
18. Kim M., Yoon S., Lee S., Ha S.A., Kim H.K., Kim J.W., et al. Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion. PloS One 2012, 7:e35100.
19. Muller I., Schonberger T., Schneider M., Borst O., Ziegler M., Seizer P., et al. Gremlin-1 is an inhibitor of macrophage migration inhibitory factor and attenuates atherosclerotic plaque growth in apoe-/- mice. JBiol Chem 2013, 288:31635-31645.
20. Maciel T.T., Melo R.S., Campos A.H. The bone morphogenetic protein antagonist Gremlin promotes vascular smooth muscle cell apoptosis. JVasc Res 2009, 46:325-332.
21. Maciel T.T., Melo R.S., Schor N., Campos A.H. Gremlin promotes vascular smooth muscle cell proliferation and migration. JMol Cell Cardiol 2008, 44:370-379.
22. Chen B., Blair D.G., Plisov S., Vasiliev G., Perantoni A.O., Chen Q., et al. Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with slits and act as negative regulators of monocyte chemotaxis. JImmunol 2004, 173:5914-5917.
23. Findeisen H.M., Gizard F., Zhao Y., Qing H., Heywood E.B., Jones K.L., et al. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol 2011, 31:851-860.
24. Natarajan R. Drugs targeting epigenetic histone acetylation in vascular smooth muscle cells for restenosis and atherosclerosis. Arterioscler Thromb Vasc Biol 2011, 31:725-727.
25. Webster A.L., Yan M.S., Marsden P.A. Epigenetics and cardiovascular disease. Can J Cardiol 2013, 29:46-57.
26. Dhore C.R., Cleutjens J.P., Lutgens E., Cleutjens K.B., Geusens P.P., Kitslaar P.J., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001, 21:1998-2003.
27. Sorescu G.P., Sykes M., Weiss D., Platt M.O., Saha A., Hwang J., et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. JBiol Chem 2003, 278:31128-31135.
28. Csiszar A., Labinskyy N., Jo H., Ballabh P., Ungvari Z. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2008, 295:H569-577.
29. Ni C.W., Qiu H., Rezvan A., Kwon K., Nam D., Son D.J., et al. Discovery of novel mechanosensitive genes invivo using mouse carotid artery endothelium exposed to disturbed flow. Blood 2010, 116:e66-73.
30. Sucosky P., Balachandran K., Elhammali A., Jo H., Yoganathan A.P. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-beta1-dependent pathway. Arterioscler Thromb Vasc Biol 2009, 29:254-260.
31. Jo H., Song H., Mowbray A. Role of NADPH oxidases in disturbed flow- and BMP4-induced inflammation and atherosclerosis. Antioxid Redox Signal 2006, 8:1609-1619.
32. Vendrov A.E., Madamanchi N.R., Hakim Z.S., Rojas M., Runge M.S. Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis. Circ Res 2006, 98:1254-1263.
33. Chang K., Weiss D., Suo J., Vega J.D., Giddens D., Taylor W.R., et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow invitro in mouse aortas and in human coronary arteries: role of bone morphogenic proteinantagonists in inflammation and atherosclerosis. Circulation 2007, 116:1258-1266.
34. Koga M., Engberding N., Dikalova A.E., Chang K.H., Seidel-Rogol B., Long J.S., et al. The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice. Am J Physiol Heart Circ Physiol 2013, 305:H747-755.
35. Li G., Li Y., Liu S., Shi Y., Chi Y., Liu G., et al. Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFβ/smad dependent signaling pathway. JCell Biochem 2013, 114:2101-2113.
36. Tanaka M., Asada M., Higashi A.Y., Nakamura J., Oguchi A., Tomita M., et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. JClin Invest 2010, 120:768-777.
37. Laurila R., Parkkila S., Isola J., Kallioniemi A., Alarmo E.L. The expression patterns of Gremlin 1 and noggin in normal adult and tumor tissues. Int J Clin Exp Pathol 2013, 6:1400-1408.
38. Wang D.J., Zhi X.Y., Zhang S.C., Jiang M., Liu P., Han X.P., et al. The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. Oncol Rep 2012, 27:58-64.
39. Langenfeld E., Deen M., Zachariah E., Langenfeld J. Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin. Mol Cancer 2013, 12:129.
40. Pardali E., Waltenberger J. Monocyte function and trafficking in cardiovascular disease. Thromb Haemost 2012, 108:804-811.
41. Zernecke A., Shagdarsuren E., Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008, 28:1897-1908.
42. Liu D., Morrell N.W. Genetics and the molecular pathogenesis of pulmonary arterial hypertension. Curr Hypertens Rep 2013, 15:632-637.
43. Elliott C.G. Genetics of pulmonary arterial hypertension. Clin Chest Med 2013, 34:651-663.
44. Kim C.W., Song H., Kumar S., Nam D., Kwon H.S., Chang K.H., et al. Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells. Arterioscler Thromb Vasc Biol 2013, 33:1350-1359.
45. Cunningham N.S., Paralkar V., Reddi A.H. Osteogenin and recombinant bone morphogenetic protein 2b are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci U S A 1992, 89:11740-11744.
46. Sorescu G.P., Song H., Tressel S.L., Hwang J., Dikalov S., Smith D.A., et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 2004, 95:773-779.